NEI Research News

Researchers have developed a new prosthetic technique that can restore vision to blind mice. The approach could potentially be further developed to improve sight in blind people.

The NEI, part of the National Institutes of Health (NIH), has become the first U.S. government agency to develop a formal collaborative research and training agreement with the United Kingdom’s National Health Service (NHS).

At two years, Avastin (bevacizumab) and Lucentis (ranibizumab injection), two widely used drugs to treat age-related macular degeneration (AMD).

Researchers recently demonstrated that human blood cells can be converted into a variety of eye cells important for vision.

NantWorks LLC has released the new LookTel Recognizer app designed to help people who are blind or visually impaired recognize everyday objects by using their iPhone camera.

Around Halloween time, health experts fear that consumers will harm their eyes with unapproved decorative contact lenses.

The Argus II retinal prosthesis, developed by Second Sight, Inc., with funding from the National Eye Institute (NEI), was recognized September 8, 2011, in honor of being the 8 millionth patent issued by the United States Patent and Trademark Office.

Study estimates prevalence of vision disorders among preschool children in three ethnic groups, identifies risk factors

Treating patients with severe cases of uveitis, the fifth leading cause of vision loss in the United States, either locally with eye implants or systemically with anti-inflammatory medications improved vision similarly over two years.

Researchers are reporting results from the first year of a two-year clinical trial that Avastin, a drug approved to treat some cancers and that is commonly used off-label to treat age-related macular degeneration (AMD).